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Summary Background Everolimus is an oral mTOR-
inhibitor. Preclinical data show synergistic effects of mTOR
inhibition in combination with 5-fluorouracil-based anti-
cancer therapy. The combination of everolimus with
capecitabine seems therefore an attractive new, orally
available, treatment regimen. Patients and methods Safety,
preliminary efficacy and pharmacokinetics of everolimus in
combination with capecitabine were investigated in patients
with advanced solid malignancies. Patients were treated
with fixed dose everolimus 10 mg/day continuously, plus
capecitabine bid for 14 days in three-weekly cycles. Dose
escalation of capecitabine proceeded according to the
standard 3×3 phase I design in four predefined dose levels
(500–1,000 mg/m2 bid). Results In total, 18 patients were
enrolled. Median (range) treatment duration with ever-
olimus was 70 days (21–414). Capecitabine 1,000 mg/m2
bid combined with 10 mg/day everolimus was declared the
maximum tolerated dose, at which level one patient
developed dose-limiting toxicity (stomatitis grade 3).
Drug-related adverse events were mostly grade ≤2 and
included mainly fatigue (56%), stomatitis (50%), and hand-
foot syndrome (33%). Partial response was documented in
three patients, and four had stable disease. There was no
pharmacokinetic interaction between everolimus and cape-
citabine. Conclusion Everolimus 10 mg/day continuously
combined with capecitabine 1,000 mg/m2 bid for 14 days
every 3 weeks is a patient-convenient, safe and tolerable
oral treatment regimen. This is the first study to demon-
strate feasibility of this combination at doses with proven
single agent efficacy in a number of tumors. Prolonged
clinical benefit was observed in an encouraging 39% of
patients with advanced solid malignancies.
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Introduction
The PI3K/Akt pathway is an important intracellular
signalling pathway that is often dysregulated in multiple
types of cancers. Signal transduction of activated PI3K/Akt
is transmitted through several downstream pathways,
including the mammalian target of rapamycin (mTOR)
[1, 2]. Everolimus, an oral mTOR inhibitor, has demon-
strated antitumor properties including inhibition of cell
proliferation, cell survival and angiogenesis in preclinical
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studies [3–11]. Interestingly, in cancer cell lines synergistic
anticancer effects of mTOR inhibition were observed when
used in combination with 5-fluorouracil (5-FU) [12–15].
Recently, everolimus has been investigated as single agent in
phase I–III clinical trials in patients with advanced renal cell
carcinoma [16, 17], metastatic pancreatic cancer [18],
advanced pancreatic neuroendocrine tumors [19], metastatic
breast cancer [20], advanced non-small cell lung cancer [21],
and in patients with various advanced solid tumors [22–24].
These trials showed that treatment with everolimus contin-
uously at 10 mg per day was well tolerated and showed
biological activity with an acceptable side effect profile,
consisting of mainly stomatitis and fatigue. Overall, the
preclinical and clinical data suggest that everolimus may be
more efficacious when used in combination with other
anticancer drugs. Indeed, everolimus has been combined in
phase I–II trials with paclitaxel [25, 26], gemcitabine [27],
gefitinib [28], bevacizumab [29] and letrozole [30], and
several other early clinical trials using combinations of
everolimus with cytotoxic agents are currently ongoing.
Capecitabine is an oral pre-prodrug of 5-FU. Recently,
capecitabine combined with everolimus has been tested in
15 heavily pretreated Korean patients with advanced gastric
cancer [31]. The combination of capecitabine plus ever-
olimus seems especially attractive due to its oral availability
and easy use in an outpatient setting. This patient-friendly
approach, the preclinical synergistic effects of 5-FU-based
anticancer therapy and mTOR inhibition, plus the available
clinical experience of mTOR inhibitors in patients with
cancer served as the rationale to initiate this phase I trial of
everolimus in combination with capecitabine. The purpose
of this study was to determine the safety, tolerability and the
pharmacokinetic interaction of capecitabine and everolimus
in patients with advanced solid malignancies.
Materials and methods
Patient population
Eligible patients were aged ≥18 years with histological or
cytological confirmed solid malignancies refractory to
standard therapies, or for whom no standard treatment
existed. Other eligibility criteria included WHO perfor-
mance status ≤2, estimated life expectancy of ≥3 months,
adequate bone marrow (white blood cell count ≥3.0×109/L,
platelets ≥100×109/L) and adequate hepatic and renal
function (serum bilirubin ≤1.5 × upper limit of normal
(ULN), ALAT/ASAT ≤2.5 × ULN or in case of liver
metastases ≤5 × ULN and serum creatinine ≤150 μmol/L).
Patients were ineligible if they were known with alcoholism,
drug addiction and/or psychotic disorders that were not
suitable for adequate follow-up. Women who were pregnant
or lactating, or able to conceive but unwilling to practice
effective anticonception were also excluded. All patients gave
written informed consent. The study was approved by the
Medical Ethics Committee of the participating institutions and
was conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines.
Study design and treatment
This was a phase I, open-label, multi-center, dose escalation
study to assess the safety, dose-limiting toxicity (DLT),
maximum-tolerated dose (MTD) and the pharmacokinetic
interaction of the combination of everolimus and capecitabine.
The study was conducted at the Amsterdam Medical Center
and the Netherlands Cancer Institute (the Netherlands).
Everolimus was administered continuously twice daily (bid)
Table 1 Patient characteristics
Characteristic N %





White patients 18 100
Median age, years 61
Range 21–71
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at a fixed total oral dose of 10 mg (5 mg bid). The first 7 days
of treatment patients were treated with single agent everolimus
to reach steady state concentrations. Treatment with capecita-
bine started on day 8 and was given twice daily for 14 days
every 3 weeks. Capecitabine was dose-escalated according to
four predefined dose levels: 500, 650, 800 and 1,000 mg/m2
capecitabine bid. At least three patients per dose level were
recruited and expanded to six if one of three patients
experienced DLT. Dose escalation to the next dose level
was permitted if no DLT occurred in any of three or in ≤1 of
six patients. In case of DLT in one or more out of three, or in
two or more out of six patients, that dose level was declared
intolerable and no further dose escalation occurred. The
immediately preceding dose level was declared the MTD.
No intra-patient dose escalations were allowed. DLT was
defined as any of the following events related to study
treatment and occurring during the first treatment cycle:
neutropenia CTC grade 4 lasting more than 5 days, CTC
grade ≥4 platelets or grade 3 platelets with bleeding,
vomiting CTC grade ≥2 or any other toxicity CTC grade
≥3 (excluding alopecia), despite best supportive care.
Toxicity was graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0 and was assessed every treatment cycle. In case
of measurable disease, tumor measurements were performed
at baseline and every three cycles and were evaluated in
accordance with the Response Evaluation Criteria in Solid
Tumors (RECIST 1.0) [32].
Pharmacokinetic analysis
To determine the pharmacokinetic interaction between
everolimus and capecitabine plus metabolites, patients
received (only for pharmacokinetic purposes) one single
morning administration of capecitabine 7 days prior to start
of treatment (day −7), at the dose level that the patient
would receive at start of treatment. Plasma samples for
capecitabine were obtained on day −7 (without everolimus)
and on day 8 (with everolimus at steady state), both at
predose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 8 h after
capecitabine intake. Vice versa, blood samples for ever-
olimus were drawn on day 7 (without capecitabine) and on
day 8 (with capecitabine), both at predose and at 0.5, 1, 1.5,
2, 3, 4, 6, 9 and 12 h after administration of everolimus. In
addition, trough concentrations (immediately before the
morning dose) of everolimus were determined on days 1, 4,
7, 8, 15, 22 and 29 to assess the formation and continuation
of steady state blood concentrations.
Everolimus was determined in whole blood by high-
performance liquid chromatography with tandem mass
spectrometry (HPLC-MS/MS) after protein precipitation
with acetonitrile using the deuterated stable isotope
everolimus-d4 as internal standard. Capecitabine and the
metabolites 5′-deoxy-5- fluorocytidine (5′-dFCR), 5′-de-
oxy-5- fluorouridine (5′-dFUR), 5-fluorouracil (5-FU) and
5-fluorodihydrouracil (FUH2) were determined in plasma
by a validated HPLC-MS/MSmethod as described previously
[33]. The pharmacokinetic parameters were calculated
using PK Solutions 2.0 (Summit Research Services,
Montrose, CO 81401; www.summitpk.com) and included
the area under the concentration-time curve (AUC),
maximum concentration (Cmax), time to Cmax (tmax), and




Descriptive statistics were used for evaluation of the safety,
efficacy and pharmacokinetic parameters using SPSS
statistics version 17.0.
Table 2 Treatment administration of the combination of everolimus and capecitabine by dose level
Dose level 1 Dose level 2 Dose level 3 Dose level 4 All
Daily dose of everolimus 10 mg 10 mg 10 mg 10 mg 10 mg
Dose of capecitabine 500 mg/m2 bid 650 mg/m2 bid 800 mg/m2 bid 1,000 mg/m2 bid 500–1,000 mg/m2 bid
Evaluable patients (N) 4 5 3 6 18
No. of treatment cycles,
Median 2.5 9 2 3 3
Range 1–15 1–15 2–3 3–19 1–19
No. of treatment days with everolimus,
Mean ± SD 108±126 192±141 50±20 168±153 141±131
Median 61 202 50 78 70
Range 21–290 29–329 30–70 65–414 21–414
DLT None None None 1 patient 1 patient
bid twice daily; DLT dose-limiting toxicity; SD standard deviation
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Results
In total, 18 patients with advanced solid tumors were
enrolled between February 2008 and June 2010. Patient
characteristics are listed in Table 1. All patients received at
least one course of treatment and were evaluable for
toxicity assessments (Table 2). Overall, a total of 114
treatment cycles were given, with a median (range) of 3
(1–19) cycles per patient. Median (range) treatment
duration with everolimus was 70 (21–414) days (Table 2).
Four patients temporarily interrupted treatment with ever-
olimus: in three cases due to adverse events and in one due
to fever. Following treatment interruption, two patients
received a 50% dose reduction of everolimus and the others
continued treatment at full dose everolimus. Dose reductions
for capecitabine were applied in nine patients, mostly due to
adverse events.
MTD and DLT
No DLT was observed up to 800 mg/m2 of capecitabine bid,
and none of the first three patients treated at the 1,000 mg/
m2 level developed DLT. Since capecitabine 1,000 mg/m2
bid was the highest predefined dose level and no DLT had
occurred thus far, it was decided to include an additional
three patients to ensure the tolerability of this level. In one
of these additional patients, a man with advanced hepato-
cellular carcinoma, severe angioneurotic edema occurred
Table 3 Possibly, probably or definitively treatment related grade 1–2 and grade 3–4 adverse events reported in 2a or more patients
Dose level Dose level 1 Dose level 2 Dose level 3 Dose level 4 Total, n (%)
No. of patients N=4 N=5 N=3 N=6 N=18 (100)
CTC grade Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Non-hematological
Fatigue 1 2 1 1 1 4 7 (39) 3 (17)
Stomatitis 1 2 1 5 9 (50)
Hand-foot syndrome 3 1 2 4 (22) 2 (11)
Nausea 2 1 1 3 (17) 1 (6)
Diarrhea 1 1 1 3 (17)
Mucositis 1 1 1 2 (11) 1 (6)
Anorexia 1 1 2 (11)
Taste loss 2 2 (11)
Neuropathy 2 2 (11)
Constipation 2 2 (11)
Skin rash 1 1 2 (11)
Hematology
Hemoglobin 3 5 3 4 15 (83)
Platelets 2 1 2 2 3 9 (50) 1 (6)
Leukocytes 1 2 2 2 7 (39)
Clinical chemistry
GGT 1 2 4 1 2 1 8 (44) 3 (17)
ASAT 2 3 2 3 10 (56)
ALAT 2 4 1 1 7 (39) 1 (6)
Hypertriglyceridemia 1 3 1 1 2 1 7 (39) 2 (11)
AP 2 1 1 3 5 (28) 2 (11)
Hypokalemia 2 2 1 5 (28)
Hyponatremia 2 1 1 1 5 (28)
Hypercholesteremia 1 2 1 4 (22)
Hyperkalemia 2 1 3 (17)
Bilirubin 1 2 1 (6) 2 (11)
Hypercalcemiaa 1 1 (6)
Numbers represent number of patients
a Grade 4 hypercalcemia occurred in one patient and was therefore included in the table
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10 days after start of treatment with everolimus (i.e. 3 days
after start of capecitabine), which could however be
excluded as being drug-related. Nonetheless, treatment with
both capecitabine and everolimus was discontinued. Edema
quickly resolved, and after 5 days of treatment interruption,
treatment was resumed and the first cycle completed with a
50% and 33% reduced dose of everolimus and capecita-
bine, respectively. Subsequently, the patient developed
mucositis grade 3 and thrombocytopenia grade 2 for which
start of the second cycle with capecitabine had to be
delayed by more than 4 weeks. This toxicity was
considered intolerable and dose-limiting. Since none of
the other five patients treated at the 1,000 mg/m2 level
developed DLT, everolimus 5 mg bid continuously combined
with capecitabine 1,000mg/m2 bid for 14 days every 3 weeks
was declared the MTD.
Safety
Table 3 lists the treatment-related CTC grade 1–2 and grade
3–4 adverse events per dose level. The most frequently
reported clinical toxicities of any grade included fatigue
(56%), stomatitis (50%), hand-foot syndrome (33%) and
nausea (22%). Other clinical toxicities included diarrhea
and mucositis (both 17%), and anorexia, taste loss,
constipation, skin rash and neuropathy (all 11%). Clinical
toxicities were never severe (≤ grade 2), with the exception
of fatigue in three patients, hand-foot syndrome in two, and
nausea in one. The six patients that developed hand-foot
syndrome were on average treated with 12.2±5.6 cycles,
while the average onset of hand-foot syndrome was after
4.6±2.3 cycles of treatment. With 20–25% dose reductions
of capecitabine, five patients were able to continue
treatment safely, and one patient went off study due to
disease progression.
Decreased hemoglobin was the most frequently reported
drug-related hematological adverse event (83%), followed
by a decrease in platelets (56%) and leukocytes (39%).
Except for one patient in dose level 1 with grade 3
thrombocytopenia, hematological toxicity remained always
≤grade 2. Elevation of gamma-glutamyltransferase (GGT)
of any grade was the most frequently reported biochemical
toxicity (61%), but appeared almost never clinically
relevant (grade≤2). Only two patients presented with
GGT grade 3, and one patient with GGT grade 4, though
her GGT-level was already grade 3 at baseline. Elevated
levels of ASAT (56%), ALAT (44%) and alkaline phospha-
tase (39%) were mostly of grade ≤2, except for one patient
in whom ALAT grade 3 occurred, and in two patients
alkaline phosphatase grade 3. Hypertriglyceridemia and
hypercholesteremia occurred in 50% and 22% of the
patients, respectively. Hypercalcemia was the second grade
4 toxicity that occurred in this study, which developed after
the 3rd cycle of treatment in a patient treated in dose level 4.
Due to clinical progression, the patient went off study and
was given pamidronate, however a possible relationship
with study medication could not be excluded.
Pharmacokinetics of everolimus and capecitabine
Blood samples for pharmacokinetic analyses of everolimus
and capecitabine plus metabolites were obtained from 17 to
14 patients, respectively. Pharmacokinetic parameters are
provided in Table 4. Everolimus showed a rapid absorption
with a median (range) time to reach maximum blood
concentrations of 1 (0.5–4) hour. Steady state for ever-
Table 4 Pharmacokinetic parameters of everolimus, capecitabine and capecitabine metabolites
Drug interaction Patients with values (N) Tmax (hr) Cmax (ng/mL) AUC (hr*ng/mL)
Everolimus without capecitabine 15 1.0 (0.5–4.0) 50±23 302±97
Everolimus with capecitabine 17 1.0 (0.5–4.0) 52±21 290±114
Capecitabine without everolimus 12 0.5 (0.5–2.0) 5627±5815 5104±3479
Capecitabine with everolimus 11 1.0 (0.5–2.0) 3864±3247 4575±2285
5′-dFCR without everolimus 14 1.0 (0.5–2.0) 6972±3069 11994±5150
5′-dFCR with everolimus 13 1.5 (0.5–4.0) 6019±2343 11513±3458
5′-dFUR without everolimus 14 1.0 (0.5–2.0) 6739±3438 9773±3113
5′-dFUR with everolimus 13 1.5 (0.5–4.0) 5357±3048 9209±3070
5-FU without everolimus 7 0.5 (0.5–4.0) 203±230 268±219
5-FU with everolimus 6 1.0 (0.5–4.0) 157±120 264±170
FUH2 without everolimus 11 2.0 (1.0–4.0) 817±301 2275±730
FUH2 with everolimus 10 2.0 (1.0–4.0) 782±482 2805±1976
tmax values are median (range), the other parameters are mean ± standard deviations
Cmax maximum concentration; Tmax time to Cmax; AUC Area under the concentration-time curve; hr hour; ng/mL nanogram per millilitre; 5′-
dFCR 5′-deoxy-5-fluorocytidine; 5′-dFUR 5′-deoxy-5-fluorouridine; 5-FU 5-fluorouracil; FUH2 5-fluorodihydrouracil
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olimus was achieved by day 4 of treatment (Fig. 1a). Steady
state was stable and remained steady at least up to day 29
(the last analyzed trough sample in this study) with an
average (±SD) concentration of C0
ss=18 (±8.5) ng/mL.
This demonstrates that no induction or inhibition of
metabolism of everolimus occurred. The mean half-life for
everolimus was t1/2=15 (±8.2) hours. Furthermore, there was
a linear relationship between the AUC of everolimus within
a 12 h dosing interval (AUC0–12) and the C0
ss concentration
(r2=0.67). No effect was observed of capecitabine on the
pharmacokinetics of everolimus (Figs. 1b and 2a). The
AUC0–12 of everolimus at steady state alone and with
capecitabine was 302±97 h*ng/mL and 290±114 h*ng/mL,
respectively. The inter-patient variability of the exposure to
everolimus expressed as the coefficient of variation (%CV)
was 36%.
Capecitabine was rapidly absorbed and the median time
to reach Cmax was 1 (0.5–2) hour. Plasma concentrations for
capecitabine metabolites peaked within 1–2 h after absorp-
tion. Since the dose of capecitabine very poorly correlated
with the AUCs of capecitabine and its main metabolites 5′-
dFCR, 5′-dFUR, 5-FU and FUH2 (r
2=0.064, 0.063, 0.063,
0.13 and 0.14, respectively), the pharmacokinetic parame-
ters were not dose-corrected (Fig. 1c). Everolimus did not
interact with the pharmacokinetics of capecitabine. The
AUC of capecitabine alone and with everolimus was 5.1±
3.5 h*mg/L and 4.6±2.3 h*mg/L, respectively. Further-
more, Cmax and tmax of capecitabine did not differ between
capecitabine alone or with everolimus. Likewise, no differ-
ences in the AUC, Cmax and tmax for capecitabine
metabolites were observed with concomitantly everolimus
(Table 4 and Fig. 2b–f). The inter-patient variabilities in the
AUC for capecitabine, 5′-dFCR, 5′-dFUR, 5-FU and FUH2
were %CV=60%, 37%, 32%, 71% and 57%, respectively.
Efficacy
Overall, 14 patients were evaluable for response by
RECIST 1.0: three patients had a confirmed partial
response, four had stable disease and seven had progression
of disease. Four patients could not be evaluated for
response, but had clinical progression of disease, and
therefore withdrew early.
Discussion
This study explored the safety, pharmacokinetics and
preliminary efficacy of the combination of capecitabine
with the oral mTOR inhibitor everolimus in patients with
advanced solid malignancies. Treatment with everolimus
combined with capecitabine was generally well tolerated
and showed an acceptable toxicity profile. In total, one DLT
(mucositis grade 3) was observed, which occurred in one
out of six patients treated at the highest dose level. In this
study, we did not reach the maximum of two or more DLTs
out of six treated patients in any dose level. The study
protocol was not amended though with an additional higher




































































Fig. 1 a Mean (standard deviation) Ctrough (C0
ss) concentrations of
everolimus in whole blood assessed at days 1, 4, 7, 8, 15, 22 and 29
from start of treatment at a dose 5 mg twice daily, b mean (standard
deviation) concentrations of everolimus in whole blood during a 12 h
interval at a dose of 5 mg bid at steady state alone (circles, solid line)
and with (triangles, dotted line) capecitabine, and c scatter plot of the
administered dose of capecitabine versus the observed area under the
plasma-concentration time curve (AUC) of capecitabine and dFCR.
(Not shown for other capecitabine metabolites for the sake of clarity)
1562 Invest New Drugs (2012) 30:1557–1565
dose level, given the fact that dose reductions of capecita-
bine were indicated in 50% of all patients during treatment.
This was mostly due to hand-foot syndrome, for which the
dose of capecitabine was reduced by 25% after on average
6 cycles of treatment. Therefore, our recommendation for
further phase II trials with this combination is everolimus
10 mg daily continuously combined with 1,000 mg/m2
capecitabine twice daily for 14 days in 3-weekly cycles.
The most commonly reported treatment-related clinical
side effects were fatigue, stomatitis and hand-foot syndrome.
Hand-foot syndrome can be attributed to capecitabine, since
this has not been observed before in single agent everolimus
trials. This well-known side effect of capecitabine resulted in
only modest dose reductions of capecitabine in our patients.
Although stomatitis is a common adverse event of both
capecitabine and everolimus as single agent as well, this
overlapping toxicity always remained mild to moderate in
severity in this study and was not dose-limiting.Moreover, the
frequency of stomatitis in this study was similar compared to
studies with single agent everolimus, which suggests that
there is no, or only a marginal additive toxic effect of
capecitabine.
The frequency of fatigue was similar to that of single
agent studies with everolimus as well [21–24]. Other
adverse events included, diarrhea, anorexia, taste loss,
neuropathy and skin rash, but remained non-severe. While
in this study the oral treatment regimen of everolimus
combined with capecitabine appeared safe and feasible, it is
of note that a previous phase I study in which the
intravenous mTOR inhibitor temsirolimus was combined
with infusional 5-FU and leucovorin, stomatitis/mucositis
occurred at all dose-levels and was dose-limiting. More-
over, this combination also resulted in treatment-related
fatal bowel perforation in two patients [34]. Similarly,
another phase I study reported that everolimus 20 mg per
week combined with the antimetabolite gemcitabine
600 mg/m2 on days 1, 8 and 15 in 4-weekly cycles was
not tolerated due to severe myelosuppression [27]. However,
no such unexplained severe toxicities were observed in our
study, which has important implications for further studies.
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Fig. 2 Individual patient area
under the concentration-time
curve (AUC) of a everolimus in
whole blood without and with
capecitabine, b capecitabine in
plasma without and with
everolimus, c dFCR in plasma
without and with everolimus,
d dFUR in plasma without and
with everolimus, e 5-FU in
plasma without and with
everolimus and f FUH2 in
plasma without and with
everolimus
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Similarly to what we report in this trial, both previous studies
did not show a pharmacokinetic interaction between the
mTOR inhibitor and the antimetabolite. This suggests that
drug interactions at a pharmacodynamic level, or schedule
differences might explain the observed variations in severity
of overlapping toxicities when different mTOR inhibitors
and cytotoxic antimetabolites are combined.
Lim et al. recently published their trial of everolimus
combined with capecitabine in Korean patients with
advanced gastric cancer [31]. In contrast to their findings
of a rather low maximum-tolerated dose (capecitabine
650 mg/m2), our study is the first to demonstrate the
feasibility of this combination at doses with proven single
agent efficacy in a number of tumors. This surprisingly large
difference (650 mg/m2 versus 1,000 mg/m2 capecitabine bid)
between the studies might possibly be caused by the
gastrectomy in more than half of the patients in the Korean
trial already had undergone. It is known that gastrectomy
results in a higher systemic exposure and higher Cmax to
capecitabine, possibly affecting tolerability [35].
The pharmacokinetic profile of everolimus assessed in
this study showed a comparable absorption, systemic
exposure, and trough concentration as in other white and
Japanese patient cohorts treated with 10 mg everolimus per
day [22, 23, 25]. The absorption was relatively fast with a
median time to Cmax of 1 h, and steady state was reached
within 4 days of treatment. Likewise, capecitabine was
rapidly absorbed, and the AUC, Cmax and time to Cmax
were in line with previously reported data [36].
Since this was a phase I study, efficacy was not a
primary endpoint; nonetheless, 14 patients were evaluable
for response. In seven patients a clinical response, including
prolonged disease stabilization was achieved. The three
patients with a partial response (two patients with pancre-
atic cancer) and half of patients with stable disease had not
received any prior chemotherapy at study entry. But
because of the minimal survival advantage of gemcitabine
in pancreatic cancer, first line treatment with experimental
anticancer therapy is considered a reasonable alternative in
this group of patients. Obviously, the relative contribution
of everolimus to this clinical benefit in these patients is
difficult to determine. However, previous studies with
single agent everolimus rarely showed better responses
than prolonged disease stabilization.
In conclusion, we showed that everolimus twice daily in
a total dose of 10 mg/day (5 mg bid) continuously
combined with capecitabine 1,000 mg/m2 for 14 days every
3 weeks is a safe and tolerable oral treatment regimen, and
achieved prolonged clinical benefit in a significant number
of patients. Toxicities were generally mild to moderate
severe and were well manageable. No unexplained severe
toxicities were reported, and no pharmacokinetic interaction
between everolimus and capecitabine was observed. There-
fore, the results obtained in this study provided for us a solid
basis for our ongoing phase II trial of everolimus and
capecitabine in pancreatic cancer patients (Trial identifier
NTC01079702. Moreover, the interesting balance between
efficacy and burden on the patient of this treatment combina-
tion is attractive to investigate in other tumor types as well.
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